ON's China EV SiC Traction Offers Glimmer of Hope, But Deep Risks Remain

What happened

ON Semiconductor is seeing accelerating adoption of its silicon carbide power devices in new Chinese EV models and next-generation platforms, providing a positive demand signal in its largest end market. However, the company remains deep in a cyclical trough with non-GAAP gross margins stuck around 38%, far from its 53% 2027 target, and auto revenue outside China still weak. A major $6B buyback authorization announced in November 2025 raises the stakes: aggressive capital returns could boost per-share metrics but also risk balance sheet strain if the recovery stalls. The master report values the stock around $60 with a WAIT rating, citing limited margin of safety, LTSA amendment risk, and underutilization of high-cost SiC fabs. While China SiC wins are a welcome step, they do not yet de-risk the broader recovery thesis or justify chasing the stock at current levels.

Implication

Investors should recognize that the China SiC traction is a positive but still nascent signal and does not alone validate the ambitious 2027 margin targets. The core issue is utilization: fab rates at ~74% need to reach high-70s to mid-80s to drive gross margin expansion, which requires a more synchronised recovery in global auto and industrial markets. The $6B buyback adds leverage to earnings per share but also reduces financial flexibility; if the recovery disappoints, buybacks may crowd out necessary capex for SiC expansion. The master report's base case of $65 by 2027 assumes moderate recovery; the current price of ~$60 leaves little upside for the risk taken, especially with a 30% bear case at $50. A disciplined investor should wait for evidence of sustained margin improvement (low-40s gross margin) and sequential revenue growth before adding positions, with an attractive entry closer to $50.

Thesis delta

The China SiC news modestly reduces downside risk for ON's auto segment but does not change the fundamental valuation or margin trajectory. The bull case probability may edge up from 25% toward 30%, but the base case remains anchored to a gradual recovery with significant execution risk. The thesis shifts from 'wait for any recovery sign' to 'wait for broader recovery confirmation,' as the China data point alone is insufficient to re-rate the stock.